Índice

• • ·Conflict in Ukraine and its impact on cancer care

    Página :439

     
• • ·Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial

    Página :440-441

    Dearbhaile M O’Donnell

     
• • ·De-escalating elective nodal irradiation for nasopharyngeal carcinoma

    Página :441-443

    Jacob A Miller, Beth M Beadle, Michael F Gensheimer, Quynh-Thu Le

     
• • ·Pre-emptive or reactive? PROMPT spinal screening in metastatic castration-resistant prostate cancer

    Página :443-444

    Shankar Siva, Muhammad Ali, Mathias Guckenberger

     
• • ·ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma

    Página :445-446

    Marjorie G Zauderer, Michael Offin

     
• • ·Improving cancer care for people with disabilities

    Página :446-447

    Cheryl Reeves, David Collingridge

     
• • ·Al-Nawati tragedy: a 16-year-old patient with leukaemia and no access to cancer care

    Página :447-449

    Faten Amer

     
• • ·Quality of data from cancer registries in the Eastern Mediterranean region

    Página :449-451

    Eman Alkhalawi, Ariana Znaor, Ali Saeed Al-Zahrani

     
• • ·Pulling the investment levers on implementation research in oncology

    Página :451-452

    Partha Basu, Andre L Carvalho, Maribel Almonte, Véronique Chajès, Elisabete Weiderpass

     
• • ·Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials

    Página :452-454

    Alessandro Ottaiano, Mariachiara Santorsola, Federica Caracò, Michele Caraglia, Guglielmo Nasti

     
• • ·Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

    Página :e156

    Joe Y Chang, Vivek Verma, James W Welsh, Silvia C Formenti

    
• • ·Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

    Página :e157

    Maria Ochoa-de-Olza, Jean Bourhis, George Coukos, Fernanda G Herrera

    
• • ·Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC

    Página :e158

    Nan Bi, Yu Wang, Luhua Wang

     
• • ·Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC – Author’s reply

    Página :e159

    Yi-Long Wu

    
• • ·Consequences of US FDA approval decisions in high-income countries

    Página :e160

    Kristina Jenei

    
• • ·Correction to Lancet Oncol 2022; 23: 382–92

    Página :e161

    
• • ·Correction to Lancet Oncol 2022; 23: 393–405

    Página :e161

    
• • ·Correction to Lancet Oncol 2022; 23: 416–27

    Página :e161

    
• • ·Correction to Lancet Oncol 2022; 23: 501–13

    Página :e161

    
• • ·Cancer control in Botswana

    Página :455

    Manjulika Das

     
• • ·Inequality in childhood cancer care worldwide

    Página :456

    Talha Khan Burki

     
• • ·Decentralisation to improve cancer services in DR Congo

    Página :457

    Manjulika Das

     
• • ·Consequences of the crisis in Ukraine on cancer care

    Página :458

    Talha Khan Burki

     
• • ·Qatar Red Crescent Society provides cancer drugs to the Palestinian Ministry of Health

    Página :459

    Sharmila Devi

     
• • ·2-week cancer target to be scrapped in England in overhaul of NHS standards

    Página :e162

    Emma Wilkinson

     
• • ·SSO 2022 International Conference on Surgical Cancer Care

    Página :e163

    Márcia Costa

    Esquema Esquema  
• • ·Cancer research collaboration between the UK and the USA: reflections on the 2021 G20 Summit announcement

    Página :460-462

    Richard Sullivan, Grant Lewison, Julie Torode, Peter T Kingham, Murray Brennan, Lawrence N Shulman, Mark Lawler, Ajay Aggarwal, Julie Gralow

      
• • ·ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer

    Página :463-464

    Daisuke Kotani, Yoshiaki Nakamura, Takao Fujisawa, Hideaki Bando, Naoya Sakamoto, Amber L Johns, Keunchil Park, ICGC-ARGO, Raffaella Casolino, Takayuki Yoshino, Andrew V Biankin, Andrew V Biankin, Lincoln D Stein, Keunchil Park, Rita T Lawlor, Amber L Johns, Jan O Korbel, Nik Zeps, Mark A Rubin, Marco A Marra, Olivier Elemento, Steven Gallinger, David Tuveson, Lorenz Trumper, Raphael Koch, Aldo Scarpa, Paul Brennan, Christian Pilarsky, Sergey Nikolaev, Sun-Soo Yoon, Eun Sook Lee, Tatsuhiro Shibata, Xiaojian Wu, Jianmin Wu, Qimin Zhan, Wai Poon, Takayuki Yoshino, Khawla S. Al-Kuraya, Rosalind Eeles, Rebecca Fitzgerald, Carlos Caldas, Jean Abraham, David K Chang

    Esquema Esquema   
• • ·Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

    Página :465-478

    Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Amit M Oza

    Resumen Resumen Esquema Esquema   
• • ·Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial

    Página :479-490

    Ling-Long Tang, Cheng-Long Huang, Ning Zhang, Wei Jiang, Yi-Shan Wu, Shao Hui Huang, Yan-Ping Mao, Qing Liu, Ji-Bin Li, Shao-Qiang Liang, Guan-Jie Qin, Wei-Han Hu, Ying Sun, Fang-Yun Xie, Lei Chen, Guan-Qun Zhou, Jun Ma

    Resumen Resumen Esquema Esquema   
• • ·PD-1 blockade with pembrolizumab in classic or endemic Kaposi’s sarcoma: a multicentre, single-arm, phase 2 study

    Página :491-500

    Julie Delyon, Lucie Biard, Marion Renaud, Matthieu Resche-Rigon, Jérôme Le Goff, Stéphane Dalle, Valentine Heidelberger, Laetitia Da Meda, Laurie Toullec, Guislaine Carcelain, Samia Mourah, Sophie Caillat-Zucman, Vincent Allain, Maxime Battistella, Céleste Lebbe

    Resumen Resumen Esquema Esquema   
• • ·Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial

    Página :501-513

    David Dearnaley, Victoria Hinder, Adham Hijab, Gail Horan, Narayanan Srihari, Philip Rich, J Graeme Houston, Ann M Henry, Stephanie Gibbs, Ram Venkitaraman, Clare Cruickshank, Shama Hassan, Alec Miners, Malcolm Mason, Ian Pedley, Heather Payne, Susannah Brock, Robert Wade, Angus Robinson, Omar Din, Kathryn Lees, John Graham, Jane Worlding, Julia Murray, Chris Parker, Clare Griffin, Aslam Sohaib, Emma Hall, PROMPTS investigators

    Resumen Resumen Esquema Esquema   
• • ·Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis

    Página :514-520

    Kerstin N Vokinger, Thomas J Hwang, David L Carl, Yannic Laube, Wolf-Dieter Ludwig, Huseyin Naci, Aaron S Kesselheim

    Resumen Resumen Esquema Esquema   
• • ·Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis

    Página :521-530

    Darren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, Xin Hui Pan, Phoebe Tay, Wen Hui Lim, Margaret Teng, Nicholas Syn, Grace Lim, Jie Ning Yong, Jingxuan Quek, Jieling Xiao, Yock Young Dan, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark D Muthiah, Rohit Loomba, Daniel Q Huang

    Resumen Resumen Esquema Esquema   
• • ·Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index

    Página :531-539

    Gustavo A Viani, Andre G Gouveia, Vanessa F Bratti, Juliana F Pavoni, Richard Sullivan, Wilma M Hopman, Christopher M Booth, Ajay Aggarwal, Timothy P Hanna, Fabio Y Moraes

    Resumen Resumen Esquema Esquema   
• • ·Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

    Página :540-552

    Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P Van Meerbeeck, Anna K Nowak, George Blumenschein, Jonathan M Siegel, Linda Kasten, Karl Köchert, Annette O Walter, Barrett H Childs, Cem Elbi, Raffit Hassan, Dean A Fennell

    Resumen Resumen Esquema Esquema   
• • ·Cancer detection, diagnosis, and treatment for adults with disabilities

    Página :e164

    Lisa I Iezzoni

    Resumen Resumen Esquema Esquema
• • ·Cancer treatment and decision making in individuals with intellectual disabilities: a scoping literature review

    Página :e174

    Anne J Boonman, Maarten Cuypers, Geraline L Leusink, Jenneken Naaldenberg, Haiko J Bloemendal

    Resumen Resumen Esquema Esquema   
• • ·Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

    Página :e184

    Jordan Gilleland Marchak, Salome Christen, Renée L Mulder, Katja Baust, Johanna M C Blom, Tara M Brinkman, Iris Elens, Erika Harju, Nina S Kadan-Lottick, Joel W T Khor, Jurgen Lemiere, Christopher J Recklitis, Claire E Wakefield, Lori Wiener, Louis S Constine, Melissa M Hudson, Leontien C M Kremer, Roderick Skinner, Janine Vetsch, Jennifer L Lee, Gisela Michel, International Guideline Harmonization Group psychological late effects group

    Resumen Resumen Esquema Esquema   
• • ·Radiation recall after COVID-19 infection

    Página :e197

    Richard Blake Ross, Rachel A Rabinovitch